Učitavanje...
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
The chimeric anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B cell malignancies, and more recently it has emerged as a potential treatment for rheumatoid arthritis (RA), via selective B lymphocyte depletion. Experience in oncology shows that rituximab is well t...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2003
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2833440/ https://ncbi.nlm.nih.gov/pubmed/15180892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar1008 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|